Debio 0532
Alternative Names: Debio-0532Latest Information Update: 08 Mar 2024
At a glance
- Originator Debiopharm
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates; Immunotherapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 29 Feb 2024 Early research in Cancer in Switzerland (Parenteral) (Debiopharm pipeline, February 2024)
- 10 Jan 2024 Debiopharm secured an option to enter an exclusive licensing deal with SunRock Biopharma
- 26 Sep 2023 Debiopharm enters into an exclusive option and license agreement with SunRock Biopharma to advance antibody drug conjugates to treat cancers